I-123-IDAB: a new tracer for scintigraphic visualisation of malignant melanoma.
I-123-N-(2-Diethylaminoethyl) 4-lodobenzamide (I-123IDAB) has recently been introduced as a radiopharmaceutical agent in the management of patients with malignant melanoma. We tested the diagnostic potential of this substance in 5 patients suspected of having an ocular malignant melanoma. I-123-IDAB scintigraphy identified 4 patients with high tracer uptake in the pathologic eye. Three cases were confirmed histologic as a malignant melanoma, the fourth patient was submitted to radiotherapy. The amelanotic (histologically confirmed) irismelanoma of the fifth patient could not be detected. From these preliminary results we conclude that I-123-IDAB scintigraphy may be a valuable tool for establishing the diagnosis of malignant melanotic melanoma.
Lodewijks
H
H
Department of Ophthalmology, Free University of Brussels.
Everaert
H
H
Hennekes
R
R
Bossuyt
A
A
D000368:Aged; D001549:Benzamides; D002830:Choroid Neoplasms / Q000000981:diagnostic imaging*; D003287:Contrast Media; D005260:Female; D006801:Humans; D015811:Iris Neoplasms / Q000000981:diagnostic imaging*; D008297:Male; D008545:Melanoma / Q000000981:diagnostic imaging*; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000000981:diagnostic imaging; D011877:Radionuclide Imaging
D001549:Benzamides; D003287:Contrast Media; C066918:N-(2-(diethylamino)ethyl)-4-iodobenzamide